Synchronous double primary lymphoma and thyroid cancer

Abstract

Synchronous double primary malignancies of lymphoma and thyroid cancer are rare. In this retrospective study, we investigated the pathology, clinical characteristics, and treatment outcomes of patients with synchronous lymphoma and thyroid cancer. Of the 1156 newly diagnosed lymphoma patients treated in our hospital between January 1, 2016 and February 1, 2021, 8 cases had lymphoma complicated with thyroid cancer. The clinical data and treatment strategies of 8 cases with synchronous lymphoma and thyroid cancer were retrospectively analyzed. The median age of patients was 56 (25–64) years. All the 8 patients were female and papillary thyroid cancer. Only 1 patient had peripheral T-cell lymphoma, and the other 7 were B-cell lymphoma. Seven of 8 patients had normal free triiodothyronine and free thyroxine at the time of diagnosis. Seven thyroid cancer patients received total thyroidectomy and levothyroxine and the remaining 1 patient has a plan for surgery. At the last follow-up, 7 patients with B-cell lymphoma are alive; the patient with peripheral T-cell lymphoma complicated with thyroid cancer died due to lymphoma progression. Synchronous lymphoma and thyroid cancer are more predominant in women. Histologically, B-cell lymphomas and papillary thyroid cancer subtypes are more common. Attention should be paid to the presence of thyroid nodules in the diagnosis of lymphoma. Biopsy or ultrasound-guided fine needle aspiration of the suspicious thyroid nodule should be performed to exclude thyroid malignancy.

Lymphoma and Differentiated Thyroid Cancer: A Case Series

“…All patients were females and had papillary carcinoma thyroid. Five of them had DLBCL and one case each of Hodgkin lymphoma, MALT lymphoma, and Peripheral T cell lymphoma [ 6 ]. Our case series had two cases of DLBCL and HL each.…”

Adversary of DNA integrity: A long non‐coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells

“…Tumors with the inv (10)(q11;q21) may be resistant to radioiodine treatment (thyroid tumor) and to EGFR inhibitor therapy (lung cancer) 20,21 . The frequency of this inversion is significantly increased in patients who have been exposed to radiation or received chemotherapy drugs 13,22 . Also, tumors with the CCDC6‐RET oncogene are frequently found in patients with autoimmune disease of the gland 23 …”

“…20,21 The frequency of this inversion is significantly increased in patients who have been exposed to radiation or received chemotherapy drugs. 13,22 Also, tumors with the CCDC6-RET oncogene are frequently found in patients with autoimmune disease of the gland. 23 In this work, we demonstrate that lncRNA ENSG00000269945.1 (hg38 chr14:71 219 100 -71 222 724, 3625 bp long) also known as NONHSAG015373.2 (NONCODE), HSALNG0102260 (LncBook), Lnc-SIPA1L1-4 (LNCipedia) and henceforth called CASTL1 for chromosomal aberrations stimulating lncRNA 1, which contains regions complementary to sequences of 1st and 11th introns of CCDC6 and RET genes respectively, stimulates the formation of the chimeric CCDC6-RET oncogene.…”

Adversary of DNA integrity: a long non-coding RNA stimulates driver oncogenic chromosomal rearrangement in human thyroid cells

“…Tumors with the inv(10)(q11;q21) may be resistant to radioiodine treatment (thyroid tumor) and to EGFR inhibitor therapy (lung cancer) 23,24 . The frequency of this inversion is significantly increased in patients who have been exposed to radiation or received chemotherapy drugs 16,25 . Also, tumors with the CCDC6-RET oncogene are frequently found in patients with autoimmune disease of the gland 26 .…”